Product concept test for a pre-formulated botulinum toxin to assess benefits and how it might impact the treatment landscape in the clinic, and among home treating professionals. We conducted a series of semi-ethnographic interviews with target users, to map current practice across the health professional target groups and assessed the impact on current practice for a pre-formulated product.

To understand current treatment paradigms and the extent different physician groups managing osteoporosis patients treat to target and how the treatment pattern changes according to risk of fracture was a need for a client. We explored the use and benefits of community database scenarios for physicians, and their use in conjunction with and without gold standard H2H RCT data. We explored perceptions of treatment holidays among segments such as high risk osteoporosis patients and the possible implications on prescribing. Delivering a concise summary of treatment pathways across physician specialism and patient segment the client was able to tactically shift marketing focus to build on the success of new trial data.

RA Partners undertook a study to model the patient journey for men with osteoporosis with the purpose of determining unmet needs across the EU5. The study compared triggers for diagnosis and treatment initiation across physician type and country. We investigated how risk assessment and bone mineral density measurements use differ and the role of different specialities in managing patients throughout their journey. The factors influencing therapy selection and the role of injectables in the treatment paradigm and how different physicians consider the benefit/risk ratio of short and long-term therapy across all classes of medications was also modelled.

Until now regular prophylactic factor infusion has been the standard of care in the management of patients with severe heamophilia A and B. However, frequent intravenous administration is an inconvenience and frequently leads to patient dissatisfaction and nonadherence. Most patients must infuse two to three times weekly to maintain hemostatic trough levels due to the relatively short half-lives of factor VIII. The arrival of long-acting factor concentrate has been anxiously anticipated, potentially enhancing the convenience of, and adherence to, therapy.

Explaining the complex clinical trial data so it can be immediately interpreted, and recalled with ease is a common challenge in medical publishing. RA Partners interviewed haematologists across Europe to understand their interpretation and understanding of communication materials and data to finalise the material needed to make sure the graphics, data point comparisons, matched what specialists wanted to know and that the key takeouts were correctly and spontaneously recalled. Recommendations enabled the creative agency to tailor communication materials to focus on perceived value.

This project set out to examine haematologists’ needs in cellular analysis solutions and explore the analyser type, design, and current and future expected lab requirements and test parameters across haematology, morphology and flow cytometry. Walk throughs in the laboratory allowed use to understand the complexities of demands placed on lab design and to enable the client to adapt design plans to accommodate actual day-to-day lab design requirements.

A range of botulinum based products are on the market and all are regarded as offering a very straightforward treatment. Results are highly regarded for the cosmetic client and found very efficacious for medical use. RA Partners set out to understand what drives treatment allegiance in such a competitive landscape, and what are the limits preventing professionals switching brands? Is it just contractual and legacy reasons or are logistical considerations the main drivers?

With the increasing use of biologics across indications demand for new devices that meet varied patient needs is growing. Through semi-ethnographic interviews with patients and nurses we were able to understand current device usage and evaluate behaviour when using prototype designs; delivering for the client a clear recommendation on which designs should be taken into development and the drivers around which to build a coherent marketing strategy.

Endurance sports, triathlons being the most popular, are the preserve of alpha-males with high disposable incomes and a predilection for gadgets: a potentially great opportunity for product developers. The interest and market in ketone diets in endurance sport training has been rapidly evolving with new supplements and nutritional aides appearing: but the market is fickle. We undertook a market mapping study to assess the extent of opportunities for the launch of a new piece of kit for the endurance sport enthusiast a non-invasive diagnostic measurement of breath acetone as a marker for ketones in the blood.

The multi-billion dollar weight loss market is dominated by the main players – Weight Watchers and Co., but they are struggling to maintain market share having been slow to adopt to the digital world. The global recession and boom in digital apps has seen the rise of Do-It-Yourself dieting – the main growth area in an overall stagnant / declining market. Ketone based diets are currently of interest due to recent celebrity endorsement – Kim Kardashian shedding her post baby pounds. While fad diets – raspberry ketones etc. – have had some popularity, they often appear to be short lived, and disappear as quickly as their celebrity endorsement. In this rapidly changing market we conducted a study to map out the market opportunities for a potential new diet monitoring product which offers non-invasive diagnostic measurement of breath acetone – a marker for ketones in blood.

Research to create and fine tune patient profiles is a common research request. Profiles that subconsciously click with physicians aide recall and can influence prescribing choices. We conducted a series of online forums with physicians and nurses delivering profiles of the main psychosocial/ behavioural characteristics of Type 2 diabetic prandial patients.